Publicaciones en las que colabora con M. E. Alonso Sarasquete (40)

2020

  1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

2016

  1. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2015

  1. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1849, Núm. 3, pp. 353-366

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  3. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

  4. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance

    Haematologica, Vol. 99, Núm. 1, pp. 155-162

  2. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  3. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

  4. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

    Haematologica, Vol. 99, Núm. 8, pp. 1365-1372

2013

  1. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study

    British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  3. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

  4. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

  5. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

    Haematologica, Vol. 98, Núm. 4, pp. 640-648

  6. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma

    Annals of Hematology, Vol. 92, Núm. 1, pp. 97-100

2012

  1. Genomic analysis of high-risk smoldering multiple myeloma

    Haematologica, Vol. 97, Núm. 9, pp. 1439-1443

  2. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma

    European Journal of Haematology, Vol. 89, Núm. 4, pp. 328-335